Brief: Immutep Reports Final Positive Data In 2nd Line Head And Neck Squamous Cell Carcinoma

Immutep

05/06/2023 14:40

June 5 (Reuters) - Immutep Ltd  IMM.AX :
    * IMMUTEP REPORTS FINAL POSITIVE DATA IN 2ND LINE HEAD AND
NECK
SQUAMOUS CELL CARCINOMA AT ASCO 2023 ANNUAL MEETING
    * IMMUTEP LTD - DUAL IMMUNO-ONCOLOGY APPROACH IS SAFE AND
VERY
WELL TOLERATED
    * IMMUTEP LTD - FOLLOW ON TACTI-003 PHASE IIB TRIAL IN 1ST
LINE
HNSCC EXPECTED TO REPORT TOP-LINE RESULTS IN H2 OF CY2023

Source text for Eikon:  ID:nGNX8dG5SL 
Further company coverage:  IMM.AX 

 ((Reuters.Briefs@thomsonreuters.com;))